{
  "cutoff": "2026-10-13",
  "note": "Selected publication milestones, not an exhaustive history or discovery priority claim.",
  "milestones": [
    {
      "pmid": "16541194",
      "year": "2006",
      "title": "The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers.",
      "doi": "10.1358/mf.2006.28.1.962774",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16541194/",
      "interpretation": "Human cyclosporin interaction work shows dose-dependent exposure effects, an early constraint on simple supplement-safety claims."
    },
    {
      "pmid": "18397984",
      "year": "2008",
      "title": "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.",
      "doi": "10.1210/jc.2007-2404",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18397984/",
      "interpretation": "A three-month placebo-controlled T2D/dyslipidemia trial reports HbA1c and glucose benefit with ordinary berberine."
    },
    {
      "pmid": "18442638",
      "year": "2008",
      "title": "Efficacy of berberine in patients with type 2 diabetes mellitus.",
      "doi": "10.1016/j.metabol.2008.01.013",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18442638/",
      "interpretation": "The metformin pilot and uncontrolled add-on component motivate clinical research while leaving noninferiority and treatment attribution unresolved."
    },
    {
      "pmid": "18511510",
      "year": "2008",
      "title": "Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway.",
      "doi": "10.1210/en.2007-1752",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18511510/",
      "interpretation": "Acute secretion inhibition and later cell response show that dose, glucose state and timing matter for mechanism narratives."
    },
    {
      "pmid": "20298851",
      "year": "2010",
      "title": "Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics.",
      "doi": "10.1016/j.talanta.2010.01.015",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20298851/",
      "interpretation": "Patient metabolomics proposes free-fatty-acid involvement but is conservatively grouped with related earlier efficacy work."
    },
    {
      "pmid": "21870106",
      "year": "2012",
      "title": "Repeated administration of berberine inhibits cytochromes P450 in humans.",
      "doi": "10.1007/s00228-011-1108-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21870106/",
      "interpretation": "Repeated-dose healthy-human CYP probe testing verifies drug-interaction potential rather than assuming inert supplement exposure."
    },
    {
      "pmid": "24791752",
      "year": "2015",
      "title": "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.",
      "doi": "10.1007/s00394-014-0706-z",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24791752/",
      "interpretation": "A direct glutathione trial establishes body-store engagement, providing ingredient context without testing a triple stack."
    },
    {
      "pmid": "26174047",
      "year": "2015",
      "title": "Transforming berberine into its intestine-absorbable form by the gut microbiota.",
      "doi": "10.1038/srep12155",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26174047/",
      "interpretation": "Animal microbial conversion/absorption experiments propose an exposure route; broad antibiotic perturbation does not isolate clinical human mediation."
    },
    {
      "pmid": "33024120",
      "year": "2020",
      "title": "Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).",
      "doi": "10.1038/s41467-020-18414-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33024120/",
      "interpretation": "PREMOTE supplies a verified concealed twelve-week T2D placebo comparison and a separate microbial hypothesis under common antibiotic pretreatment."
    },
    {
      "pmid": "33888596",
      "year": "2021",
      "title": "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.",
      "doi": "10.1126/science.abe9985",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33888596/",
      "interpretation": "NMN improves measured muscle insulin sensitivity in prediabetic women, a component-specific result without combination evidence."
    },
    {
      "pmid": "34556670",
      "year": "2021",
      "title": "Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.",
      "doi": "10.1038/s41467-021-25952-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34556670/",
      "interpretation": "Mouse KCNH6 loss and a healthy-human acute clamp narrow a secretion mechanism; the attached correction changes an author name only."
    },
    {
      "pmid": "34923903",
      "year": "2022",
      "title": "Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.",
      "doi": "10.1080/19490976.2021.2003176",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34923903/",
      "interpretation": "A PREMOTE lipid secondary analysis illustrates why new mechanistic resolution is not a new independent efficacy trial."
    },
    {
      "pmid": "36740954",
      "year": "2023",
      "title": "Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.",
      "doi": "10.1210/clinem/dgad027",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36740954/",
      "interpretation": "Short NMN physiology produces NAD and selected risk-factor changes while several functional/metabolic endpoints remain null."
    },
    {
      "pmid": "38789831",
      "year": "2024",
      "title": "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.",
      "doi": "10.1007/s11357-024-01204-1",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38789831/",
      "interpretation": "An older-adult NMN trial has a null primary stepping endpoint alongside selected secondary walking/sleep signals."
    },
    {
      "pmid": "40029660",
      "year": "2025",
      "title": "Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial.",
      "doi": "10.1001/jamanetworkopen.2024.62185",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40029660/",
      "interpretation": "A distinct BUDCA formulation produces dose-related twelve-week T2D HbA1c benefit while weight stays stable."
    },
    {
      "pmid": "41543854",
      "year": "2026",
      "title": "Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.",
      "doi": "10.1001/jamanetworkopen.2025.54152",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41543854/",
      "interpretation": "A six-month ordinary-berberine obesity/MASLD trial is null for adiposity and glycemic measures in diabetes-free adults, limiting broad weight-loss extrapolation."
    },
    {
      "pmid": "41882153",
      "year": "2026",
      "title": "Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization.",
      "doi": "10.1038/s44325-026-00113-w",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41882153/",
      "interpretation": "Drug-response signature MR generates cardiometabolic hypotheses without directly instrumenting oral exposure or replacing clinical event trials."
    }
  ],
  "gaps": [
    "Durable ordinary-berberine efficacy and safety beyond short T2D trials under contemporary unchanged standard care",
    "Role of common antibiotic pretreatment and baseline microbial ecology in the PREMOTE response",
    "Exposure/product standardization and translation between ordinary berberine, BUDCA and botanical bundles",
    "Unique chronic human mediation versus simultaneous gut, secretion, receptor and mitochondrial effects",
    "Direct modern GLP-1 equivalence for specified weight and cardiometabolic outcomes",
    "Exact triple-stack trials and component-dismantling evidence with meaningful functional outcomes",
    "Drug interactions, formulation variability and all-comer tolerability beyond selected short-term cohorts"
  ],
  "decisive_experiment": "Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials."
}